Full Event Guide

What can you expect in 2nd Annual Hemophilia Drug Development Summit?


Conference Day 1

Wednesday, August 21 2019

Conference Day 2

Thursday, August 22 2019

Application of State-of-the-art Laboratory Techniques to an Ever-changing Hemophilia Drug Landscape

Michael Ero Chief Executive Officer & President, Machaon Diagnostics

Fitusiran, An RNAi Therapeutic Targeting Antithrombin to Restore Hemostatic Balance in People with Hemophilia

Shauna Andersson
Clinical Research Director , Sanofi Genzyme

Research and Development of Next Generation Prophylaxis

Robert Peters
Rare Blood Disorders Therapeutic Area Head, Research, Sanofi Genzyme

Significance of Neutralizing Antibodies in Gene Therapy in Hemophilia

Sander Van Deventer
Chief Scientific Officer , uniQure

A Stable & Durable Treatment for Pediatric Patients with Hemophilia

Dean Falb
Chief Scientific Officer, LogicBio

Data from a Prospective Study using FVIIIFc for ITI in Hemophilia Patients with Inhibitors

Nisha Jain
Executive Medical Director, Bioverativ, a Sanofi Company

Download the full event guide to view the entire speaker faculty, session details, partner information, pricing and discounts.